8-K: Quanterix Settles Activist Dispute, Boosts Governance

Quanterix Corporation has entered a cooperation agreement with activist investor Kent Lake, agreeing to board declassification, majority voting, and a new independent director.

Summary

• Quanterix Corporation (QTRX) and Kent Lake Partners LP (Kent Lake) entered into a Cooperation Agreement on August 4, 2025, resolving a potential proxy contest.
• Kent Lake, which beneficially owns approximately 4.4% (2,050,031 shares) of Quanterix's common stock, has withdrawn its previous director nominations and shareholder proposals.
• The Company will seek stockholder approval at the 2025 annual meeting to declassify its Board of Directors, transitioning to one-year terms for directors elected from 2026 onwards.
• Quanterix will amend its bylaws before the 2025 annual meeting to adopt a majority voting standard for uncontested director elections.
• A new independent Class I director will be appointed by December 1, 2025, identified through an executive search firm with mutual input from Quanterix and Kent Lake.
• Kent Lake has agreed to customary standstill provisions and voting commitments, including generally supporting the Board's recommendations, until 30 days prior to the nomination deadline for the 2027 annual meeting.
• Quanterix will reimburse Kent Lake for engagement and negotiation costs up to $950,000.

Sentiment

Score: 7

Explanation: The agreement resolves a potentially disruptive activist campaign, leading to enhanced corporate governance and board refreshment. This provides stability and allows management to focus on strategic objectives, which is generally positive for investor confidence. The cost of reimbursement is minor compared to the benefits of avoiding a proxy fight.

Positives

• Resolution of potential proxy contest with Kent Lake, allowing management to focus on strategy and the Akoya transaction.
• Commitment to appoint a new independent director, potentially enhancing board oversight and expertise.
• Proposed declassification of the Board and adoption of majority voting standard for uncontested elections, improving corporate governance and shareholder responsiveness.
• Kent Lake's agreement to standstill provisions and voting commitments provides stability and reduces future activist pressure for a defined period.

Negatives

• Company will incur up to $950,000 in reimbursement costs to Kent Lake for its engagement and negotiation expenses.

Risks

• Risks related to the impact of recent U.S. government policies, including reductions in federal research funding and increased tariffs.
• Risks that the Company may not realize the expected benefits of its cost reduction actions.
• Risks associated with the anticipated timing for launch of, and features of, Quanterix’s next-generation instrument, Simoa ONE.
• Risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisition of Emission, Inc. (likely a typo for Akoya Biosciences, based on context).
• Risks that Quanterix’s estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect.
• Risks related to the restatement of Quanterix’s consolidated financial statements, including risks of increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation.
• Risks related to Quanterix’s ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including its ability to remediate existing material weaknesses in its internal control over financial reporting and the timing of any such remediation.
• Quanterix’s ability to realize the intended benefits of its assay redevelopment program.
• Quanterix’s ability to retain and expand its customer base and achieve sufficient market acceptance of its products.

Future Outlook

Quanterix's future outlook includes continued focus on executing its strategy, navigating the dynamic industry environment, and maximizing the benefits of the Akoya acquisition. The Company anticipates launching its next-generation instrument, Simoa ONE, and aims to realize the intended benefits of its assay redevelopment program, while retaining and expanding its customer base.

Management Comments

• "We are pleased to have reached a constructive agreement with Kent Lake that will allow the Board and management team to remain fully focused on executing the Company’s strategy, navigating the dynamic industry environment and maximizing the benefits of the Akoya transaction." William P. Donnelly, Chairman of the Quanterix Board.
• "We look forward to working with Kent Lake to identify a new director who can help us unlock the Company’s full potential and advance our goal of changing the way disease is detected, understood and treated." William P. Donnelly, Chairman of the Quanterix Board.
• "We are confident that the addition of a new independent director and governance enhancements will benefit the Company and its stockholders and help position Quanterix for continued success." Benjamin Natter, Managing Member of Kent Lake.

Industry Context

This agreement reflects a common trend where publicly traded companies engage with activist investors to resolve governance disputes, often leading to board refreshment and enhanced shareholder rights. For Quanterix, a leader in ultra-sensitive biomarker detection, resolving such disputes allows it to maintain focus on its core business, strategic initiatives like the Akoya Biosciences acquisition, and product development, which are critical in the competitive life sciences and diagnostics industry.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Benefits from enhanced corporate governance, including board declassification and majority voting, which typically increase board accountability and shareholder influence. Resolution of activist dispute reduces uncertainty.
• **Management**: Can now focus fully on executing the Company's strategy and integrating the Akoya acquisition without the distraction of a proxy contest.
• **Board of Directors**: Will undergo refreshment with a new independent director, potentially bringing new perspectives and expertise. The declassification and majority voting changes will alter the dynamics of board elections and accountability.

Next Steps

• Retain an executive search firm to identify a potential Class I director candidate.
• Company and Kent Lake to cooperate to select and appoint a new Class I director by December 1, 2025.
• Seek stockholder approval at the 2025 annual meeting for an amendment to declassify the Board.
• Amend the Company's Restated Bylaws prior to the 2025 annual meeting to adopt a majority voting standard for uncontested director elections.

Key Dates

Recommendation

The cooperation agreement resolves a significant corporate governance dispute, which is a positive development that removes uncertainty and allows management to focus on core business. The agreed-upon governance enhancements (board declassification, majority voting, new independent director) are generally viewed favorably by institutional investors. However, this filing does not contain new financial performance data or strategic shifts that would warrant a 'buy' recommendation. The company still faces existing risks related to its business operations, market acceptance, and financial reporting, as highlighted in the forward-looking statements. Therefore, a 'hold' recommendation is appropriate, reflecting the positive resolution of a governance issue while acknowledging ongoing operational considerations.

Keywords

Quanterix, QTRX, Kent Lake, Cooperation Agreement, Corporate Governance, Board Declassification, Majority Voting, Activist Investor, SEC Filing, Biomarker Detection, Simoa Technology, Akoya Biosciences